{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T23:22:41Z","timestamp":1784330561163,"version":"3.55.0"},"reference-count":22,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","japha.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Pharmacists Association"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.japh.2023.02.015","type":"journal-article","created":{"date-parts":[[2023,2,19]],"date-time":"2023-02-19T23:08:14Z","timestamp":1676848094000},"page":"920-924","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Incidence of transaminitis in adults with cystic fibrosis taking elexacaftor\/tezacaftor\/ivacaftor"],"prefix":"10.1016","volume":"63","author":[{"given":"Marci","family":"Wood","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2066-9057","authenticated-orcid":false,"given":"Faith","family":"Babowicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7540-4961","authenticated-orcid":false,"given":"Amanda G.","family":"Kennedy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6409-3697","authenticated-orcid":false,"given":"Martine","family":"Antell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9124-8874","authenticated-orcid":false,"given":"Elizabeth","family":"Gilhooly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley J.","family":"Tompkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheela S.","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.japh.2023.02.015_bib1","first-page":"500","article-title":"CFTR modulators for the treatment of cystic fibrosis","volume":"39","author":"Pettit","year":"2014","journal-title":"P\u00a0T"},{"issue":"19","key":"10.1016\/j.japh.2023.02.015_bib2","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1056\/NEJMra043184","article-title":"Cystic fibrosis","volume":"352","author":"Rowe","year":"2005","journal-title":"N\u00a0Engl J Med"},{"issue":"22","key":"10.1016\/j.japh.2023.02.015_bib3","doi-asserted-by":"crossref","first-page":"8586","DOI":"10.3390\/ijms21228586","article-title":"Current treatment options for cystic fibrosis-related liver disease","volume":"21","author":"Staufer","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"3","key":"10.1016\/j.japh.2023.02.015_bib4","first-page":"136","article-title":"Liver disease in cystic fibrosis","volume":"9","author":"Kobelska-Dubiel","year":"2014","journal-title":"Prz Gastroenterol"},{"issue":"7","key":"10.1016\/j.japh.2023.02.015_bib5","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1164\/rccm.201207-1160OE","article-title":"Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health","volume":"187","author":"Mogayzel","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"10.1016\/j.japh.2023.02.015_bib6","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1513\/AnnalsATS.201707-539OT","article-title":"Cystic Fibrosis Foundation pulmonary guidelines. Use of cystic fibrosis transmembrane conductance regulator modulator therapy in patients with cystic fibrosis","volume":"15","author":"Ren","year":"2018","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.japh.2023.02.015_bib7","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.3389\/fphar.2019.01662","article-title":"CFTR modulators: the changing face of cystic fibrosis in the era of precision medicine","volume":"10","author":"Lopes-Pacheco","year":"2019","journal-title":"Front Pharmacol"},{"issue":"19","key":"10.1016\/j.japh.2023.02.015_bib12","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa1908639","article-title":"Elexacaftor-Tezacaftor-Ivacaftor for cystic fibrosis with a single Phe508del allele","volume":"381","author":"Middleton","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"10212","key":"10.1016\/j.japh.2023.02.015_bib13","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(19)32597-8","article-title":"Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial","volume":"394","author":"Heijerman","year":"2019","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.japh.2023.02.015_bib14","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1056\/NEJMoa2100665","article-title":"Triple therapy for cystic fibrosis Phe508del-gating and-residual function genotypes","volume":"385","author":"Barry","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.japh.2023.02.015_bib15","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.jcf.2021.05.017","article-title":"A\u00a0case of self-limited drug induced liver injury under treatment with elexacaftor\/tezacaftor\/ivacaftor: when it is worth taking the risk","volume":"20","author":"Stylemans","year":"2021","journal-title":"J\u00a0Cyst Fibros"},{"issue":"2","key":"10.1016\/j.japh.2023.02.015_bib16","doi-asserted-by":"crossref","first-page":"e99","DOI":"10.1016\/j.jcf.2021.07.001","article-title":"Drug-induced liver injury from elexacaftor\/ivacaftor\/tezacaftor","volume":"21","author":"Lowry","year":"2022","journal-title":"J\u00a0Cyst Fibros"},{"issue":"6","key":"10.1016\/j.japh.2023.02.015_bib17","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1097\/MCP.0b013e3283659f45","article-title":"The impact of medication adherence on lung health outcomes in cystic fibrosis","volume":"19","author":"Eakin","year":"2013","journal-title":"Curr Opin Pulm Med"},{"issue":"2","key":"10.1016\/j.japh.2023.02.015_bib18","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.1016\/j.jcf.2017.09.006","article-title":"Ivacaftor withdrawal syndrome in cystic fibrosis patients with the G551D mutation","volume":"17","author":"Trimble","year":"2018","journal-title":"J\u00a0Cyst Fibros"},{"issue":"3","key":"10.1016\/j.japh.2023.02.015_bib19","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.jcf.2021.07.021","article-title":"Ivacaftor withdrawal syndrome: a potentially life-threatening consequence from a life-saving medication","volume":"21","author":"Clegg","year":"2022","journal-title":"J\u00a0Cyst Fibros"},{"issue":"2","key":"10.1016\/j.japh.2023.02.015_bib20","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1164\/rccm.201906-1227OC","article-title":"Real-life safety and effectiveness of Lumacaftor-Ivacaftor in patients with cystic fibrosis","volume":"201","author":"Burgel","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"10.1016\/j.japh.2023.02.015_bib21","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research Electronic Data Capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"J\u00a0Biomed Inform"},{"issue":"3","key":"10.1016\/j.japh.2023.02.015_bib22","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1056\/NEJMra1816149","article-title":"Drug-induced liver injury-types and phenotypes","volume":"381","author":"Hoofnagle","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.japh.2023.02.015_bib23","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s40264-018-0743-2","article-title":"Drug-induced liver injury: highlights of the recent literature","volume":"42","author":"Real","year":"2019","journal-title":"Drug Saf"},{"issue":"5","key":"10.1016\/j.japh.2023.02.015_bib24","doi-asserted-by":"crossref","first-page":"E6","DOI":"10.1002\/ppul.23971","article-title":"Sensitivity of ivacaftor to drug-drug interactions with rifampin, a cytochrome P450 3A4 inducer","volume":"53","author":"Guimbellot","year":"2018","journal-title":"Pediatr Pulmonol"},{"issue":"8","key":"10.1016\/j.japh.2023.02.015_bib26","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1002\/ppul.24348","article-title":"Patients and families experience with pharmacist care at cystic fibrosis foundation accredited clinics","volume":"54","author":"Young","year":"2019","journal-title":"Pediatr Pulmonol"},{"issue":"3","key":"10.1016\/j.japh.2023.02.015_bib27","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.japh.2018.01.006","article-title":"The pharmacist's role in supporting people living with cystic fibrosis","volume":"58","author":"Abraham","year":"2018","journal-title":"J\u00a0Am Pharm Assoc (2003)"}],"container-title":["Journal of the American Pharmacists Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1544319123000559?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1544319123000559?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T05:51:45Z","timestamp":1761544305000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1544319123000559"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S1544319123000559"],"URL":"https:\/\/doi.org\/10.1016\/j.japh.2023.02.015","relation":{},"ISSN":["1544-3191"],"issn-type":[{"value":"1544-3191","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Incidence of transaminitis in adults with cystic fibrosis taking elexacaftor\/tezacaftor\/ivacaftor","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Pharmacists Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.japh.2023.02.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 American Pharmacists Association\u00ae. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}